David M. Mens
A5092402591- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Colorectal Cancer Screening and Detection
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
- Appendicitis Diagnosis and Management
- Abdominal Surgery and Complications
- Ureteral procedures and complications
- Gastric Cancer Management and Outcomes
Erasmus University Rotterdam
2023-2024
Royal Prince Alfred Hospital
2024
Erasmus MC
2023
Erasmus MC Cancer Institute
2023
Amphia Ziekenhuis
2021
Abstract Background During the COVID-19 pandemic, a decrease in number of patients presenting with acute appendicitis was observed. It is unclear whether this caused shift towards more complicated cases appendicitis. We compared cohort diagnosed during 2020 pandemic 2019 control cohort. Methods retrospectively included consecutive adult 21 hospitals (March 15 – April 30, 2020) and 2019). Primary outcome proportion Secondary outcomes prehospital delay, severity, postoperative complication...
Aims Lymph node metastases (LNM) are one of the most important prognostic indicators in solid tumours and a major component cancer staging. Neoadjuvant therapy might influence nodal status by induction regression. Our aim is to determine prevalence role regression LNM on outcomes patients with rectal cancer. Methods results Four independent study populations treated similar regimens chemoradiotherapy were pooled together obtain total cohort 469 patients. Post‐treatment (ypN) signs tumour...
To establish globally applicable benchmark outcomes for pelvic exenteration (PE) in patients with locally advanced primary (LARC) and recurrent rectal cancer (LRRC), using achieved at highly specialised centres.
Journal Article Locally recurrent rectal cancer: oncological outcomes of neoadjuvant chemoradiotherapy with or without induction chemotherapy Get access Stefi Nordkamp, Nordkamp Department Surgery, Catharina Hospital, Eindhoven, the NetherlandsGROW School for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands Correspondence to: Michelangelolaan 2, 5623 EJ, (e-mail: stefi.nordkamp@catharinaziekenhuis.nl) https://orcid.org/0000-0002-9738-8691 Search other works by this...
A minimally invasive lobectomy (MIL) is the standard treatment for stage I non-small cell lung cancer (NSCLC) in medically operable patients. Stereotactic ablative radiotherapy (SABR) recommended inoperable patients and has been proposed as a potential alternative well. Here, we present results of feasibility study preparation nationwide retrospective cohort study, comparing outcomes between both modalities.In this data from with clinical NSCLC treated MIL or SABR 2014-2015 were retrieved...
Partial response to neoadjuvant chemoradiotherapy (CRT) presents with one of two main patterns: shrinkage or fragmentation. This study investigated the relevance these patterns in rectal cancer, correlation other indicators, and outcome.The included a test (n = 197) validation cohort 218) post-CRT patients adenocarcinoma not otherwise specified partial response. Response were scored by independent observers using previously developed three-step flowchart. Tumour regression grading (TRG) was...
Abstract Background Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but associated significant damage surrounding healthy tissue that can severely impact quality life. Additionally, a proportion (hardly) benefit from CRT. We aim develop diagnostic innovation, using DNA-methylation, which enable more selective and thereby effective use available therapies for...